Daniel Barenboim, Parkinson's disease
The Google cofounder has donated more than $1.5 billion to Parkinson’s research. Now, as he takes on autism, he’s also ...
The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...
People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.
We spend billions searching for the cures to chronic illnesses while neglecting research that could make the daily lives of ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
Ben Foster has revealed the brutally honest chat he had with Phil Parkinson before sensationally joining Wrexham for a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results